Last viewed:
BXRX
Prices are updated after-hours
BXRX
|
$0.1864
-54.35%
330K
|
Health Technology
(0.0% 1d)
(0.0% 1m)
(-89.5% 1y)
(0.0% 2d)
(0.0% 3d)
(0.0% 7d)
(-0.34%
volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 1,710,656
http://www.baudaxbio.com
Sec
Filling
|
Patents
| 25 employees
Baudax Bio, Inc. is a pharmaceutical company focusing on developing and commercializing products for acute care settings. The company was founded in 2015 and is headquartered in Malvern, PA.
Drugs
Anjeso
(meloxicam )
add to watch list
Paper trade
email alert is off
Press-releases
Delisting of Securities of Sono Group N.V.; Baudax Bio, Inc.; Comera Life Sciences Holdings, Inc.; Missfresh Limited; Rose Hill Acquisition Corporation; Axcella Health; Zivo Bioscience, Inc.; Sonic Foundry, Inc.; Mobiquity Technologies, Inc.; Cuentas, Inc.; micromobility.com Inc.; Harbor Custom Development, Inc.; Nogin, Inc.; Disruptive Acquisition Corporation I; Ebix, Inc.; and Aurora Technology Acquisition Corp. from The Nasdaq Stock Market
Published: 2024-02-13
(Crawled : 21:00)
- globenewswire.com
SEVCQ
|
$0.035
51.57%
45K
|
n/a
| -38.46%
| O: -7.69%
H: 46.67%
C: 11.83%
CMRA
|
$0.041
70.59%
3K
|
n/a
| -11.11%
| O: 0.0%
H: 0.0%
C: -8.0%
MOBQ
|
$0.8999
-65.45%
13K
|
| 87.8%
| O: -14.63%
H: 17.14%
C: 8.57%
NDAQ
|
$61.51
0.69%
0.68%
2.8M
|
Finance
| 10.41%
| O: 0.65%
H: 0.23%
C: -0.45%
nasdaq
rose
life
corporation
group
acquisition
sciences
technology
market
Baudax Bio Announces Corporate Update
Published: 2023-10-18
(Crawled : 12:00)
- globenewswire.com
BXRX
|
$0.1864
-54.35%
330K
|
Health Technology
| -15.27%
| O: 25.86%
H: 1.16%
C: -18.31%
update
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors
Published: 2023-09-28
(Crawled : 12:00)
- globenewswire.com
BXRX
|
$0.1864
-54.35%
330K
|
Health Technology
| -37.87%
| O: 87.57%
H: 38.62%
C: -19.67%
ti-168
fda
drug
granted
treatment
designation
Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference
Published: 2023-09-07
(Crawled : 12:00)
- globenewswire.com
BXRX
|
$0.1864
-54.35%
330K
|
Health Technology
| -51.71%
| O: 1.04%
H: 2.56%
C: 1.28%
conference
global
Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
Published: 2023-08-23
(Crawled : 12:00)
- globenewswire.com
BXRX
|
$0.1864
-54.35%
330K
|
Health Technology
| -58.39%
| O: 6.03%
H: 0.0%
C: -4.53%
distribution
Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Published: 2023-08-17
(Crawled : 12:00)
- globenewswire.com
BXRX
|
$0.1864
-54.35%
330K
|
Health Technology
| -66.42%
| O: -6.11%
H: 5.53%
C: 0.4%
nasdaq
direct
offering
Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
Published: 2023-08-16
(Crawled : 12:00)
- globenewswire.com
BXRX
|
$0.1864
-54.35%
330K
|
Health Technology
| -67.59%
| O: -3.48%
H: 0.0%
C: 0.0%
business
update
financial
results
Baudax Bio Acquires TeraImmune, Inc.
Published: 2023-06-30
(Crawled : 12:00)
- globenewswire.com
BXRX
|
$0.1864
-54.35%
330K
|
Health Technology
| -64.17%
| O: 23.03%
H: 123.42%
C: 82.81%
Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000
Published: 2023-06-07
(Crawled : 13:20)
- globenewswire.com
BXRX
|
$0.1864
-54.35%
330K
|
Health Technology
| -66.71%
| O: 7.16%
H: 5.23%
C: -2.57%
bx1000
positive
trial
results
phase 2
Baudax Bio Announces Date of Reconvened Annual Meeting
Published: 2023-06-06
(Crawled : 13:00)
- globenewswire.com
BXRX
|
$0.1864
-54.35%
330K
|
Health Technology
| -65.48%
| O: 1.85%
H: 2.91%
C: 1.8%
meeting
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount